Your browser doesn't support javascript.
loading
Advances in patent applications related to allergen immunotherapy.
Silva, Eduardo Santos da; Pinheiro, Carina Silva; Quintella, Cristina Maria; Ferreira, Fatima; C Pacheco, Luis Gustavo; Alcântara-Neves, Neuza Maria.
Afiliação
  • Silva ES; a Instituto de Ciências da Saúde - ICS , Universidade Federal da Bahia (UFBA) , Salvador , Bahia , Brazil.
  • Pinheiro CS; b Programa de Pós-Graduação em Biotecnologia da Rede Nordeste de Biotecnologia (RENORBIO) , Universidade Estadual do Ceará , Fortaleza , Brazil.
  • Quintella CM; a Instituto de Ciências da Saúde - ICS , Universidade Federal da Bahia (UFBA) , Salvador , Bahia , Brazil.
  • Ferreira F; c Instituto de Química , Universidade Federal da Bahia , Salvador , Bahia , Brazil.
  • C Pacheco LG; d Department of Molecular Biology , University of Salzburg , Salzburg , Austria.
  • Alcântara-Neves NM; a Instituto de Ciências da Saúde - ICS , Universidade Federal da Bahia (UFBA) , Salvador , Bahia , Brazil.
Expert Opin Ther Pat ; 26(6): 657-68, 2016 Jun.
Article em En | MEDLINE | ID: mdl-27011299
INTRODUCTION: Allergies are among the most prevalent chronic diseases worldwide. Allergen-specific immunotherapy is used as an alternative treatment to pharmacotherapy. These immunotherapies are performed with crude extracts, which have disadvantages when compared to the new approaches, among them are recombinant proteins and hypoallergens. This review aims to assess immunotherapy for allergies through patent application analysis spanning recent decades. AREAS COVERED: Patents referring to allergen immunotherapies used in allergy treatment. Data were obtained from the Espacenet® website, using the Cooperative Patent Classification (CPC) system. Two-hundred-and-one patent applications were analyzed, taking into consideration their classification by the type of technology and applicant. EXPERT OPINION: Allergen-specific immunotherapy represents the only potentially curative therapeutic intervention for the treatment of allergic diseases. The extract-based immunotherapy is being replaced by the use of recombinant allergens, highlighting the hypoallergenic forms, which have low IgE-binding while retaining T-cell reactivity. It is expected that the development of hypoallergens will expand the scope of allergen-specific immunotherapy, especially if associated with alternative systems for expression and delivery systems with future potential. Furthermore, these new developments will likely address the problem of long-term protocols in allergen-specific immunotherapy, thus allowing better patient adherence and compliance.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alérgenos / Dessensibilização Imunológica / Hipersensibilidade Tipo de estudo: Guideline / Health_technology_assessment Limite: Humans Idioma: En Revista: Expert Opin Ther Pat Assunto da revista: TERAPEUTICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alérgenos / Dessensibilização Imunológica / Hipersensibilidade Tipo de estudo: Guideline / Health_technology_assessment Limite: Humans Idioma: En Revista: Expert Opin Ther Pat Assunto da revista: TERAPEUTICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido